-
Mashup Score: 0Treatment options for rare bleeding disorders - 3 year(s) ago
Suchitra Acharya, MD, MBBS, Northwell Health, New Hyde Park, New York, NY, provides an overview of the current treatment landscape…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0New agents and therapeutic options for T-cell lymphoma - 3 year(s) ago
Jia Ruan, MD, PhD, Weill Cornell Medicine, New York, NY, discusses the new agents in active development for highly heterogeneous…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Jia Ruan of @WeillCornell comments on new possibilities for peripheral T-cell #Lymphoma like anti-CD30, epigenetic-targeting agents, and PI3 kinase or JAKi. 👉Watch video here: https://t.co/Ya3Qucrvcu #LYMsm #NonHodgkinLymphoma #ImmunoOnc #HemOnc #LLMCongress2021
-
-
Mashup Score: 2Challenges in treating AML - 3 year(s) ago
Sangmin Lee, MD, Weill Cornell Medicine, New York, NY, discusses hurdles in treating patients with acute myeloid leukemia (AML). Current…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Sangmin Lee of @WeillCornell comments on the challenges for optimal treatments for acute myeloid #Leukemia in older patients. Watch here: https://t.co/0LzWjavoIt #AMLsm #ImmunoOnc #HemOnc #LLMCongress2021
-
-
Mashup Score: 1
During the Lymphoma, Leukemia & Myeloma 2021 Virtual Congress, the MM hub was pleased to speak to Rafael Fonseca, Mayo Clinic, Phoenix, US. We asked, Why assessing t(11;14) can be the first step towards personalized therapy in MM?
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📹 #LLMCongress2021 | The @MM_Hub was pleased to speak to @Rfonsi1, @MayoCancerCare. We asked, Why assessing t(11;14) can be the first step towards personalized therapy in multiple #myeloma? 👀 #mmsm https://t.co/56ADf3PBMV
-
-
Mashup Score: 0
Thomas Kipps, MD, PhD, UC San Diego, Moores Cancer Center, La Jolla, CA, discusses data from clinical trials that have…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
@VJHemOnc caught up w/ Thomas Kipps (@UCSDCRCERA) on the latest clinical trial findings in #CLL ✨Discussing fixed duration treatments, combination therapy & novel targets: 👉https://t.co/TUSuOoBmge @UCSanDiego #LLMCongress2021 #HemOnc #Leukemia #Leusm #CLLsm #TrialUpdate #CTSM
-
-
Mashup Score: 0Current treatments and new developments for adult ATLL - 3 year(s) ago
Adrienne Phillips, MD, Weill Cornell Medicine, New York, NY, discusses current treatments and novel strategies for adult T-cell leukemia/lymphoma (ATLL)….
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Adrienne Phillips (@dr_aphillips) of @WeillCornell discusses current treatments and novel strategies for adult T-cell #Leukemia/#Lymphoma, addressing allo-HSCT and mogamulizumab. 👉Watch here: https://t.co/5vu4DgNxYs👈 #Leusm #LYMsm #ImmunoOnc #HemOnc #LLMCongress2021
-
-
Mashup Score: 0Future directions for the treatment of WAHA - 3 year(s) ago
Catherine Broome, MD, Lombardi Cancer Center, Washington, DC, discusses the developments in the treatment landscape for warm autoimmune hemolytic anemia…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Catherine Broome of @LombardiCancer discusses BTK and SYK inhibitors as potential treatments for warm autoimmune hemolytic #Anemia. ➡️Watch here: https://t.co/FCUeCGWo3d #BleedingDisorders #ImmunoOnc #HemOnc #LLMCongress2021
-
-
Mashup Score: 0Treatment sequencing options for recurrent CLL - 3 year(s) ago
Michael Choi, MD, UC San Diego Health, San Diego, CA, discusses treatment options for patients with recurrent chronic lymphocytic leukemia…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Michael Choi of @UCSDHealth discusses alternative BTK inhibitors, CAR T-cells and allo-SCT for patients with recurrent CLL who have progressed. 👉Watch here: https://t.co/YydsWwXu1x👈 #Leukemia #CLLsm #ImmunoOnc #CART #BMTsm #HemOnc #LLMCongress2021
-
-
Mashup Score: 0
Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, gives an update on patient-specific targeted therapy in multiple myeloma, including the history…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Rafael Fonseca (@Rfonsi1) of @MayoClinicAZ_IR talks about the development of agents targeting translocation-associated mutations in #MultipleMyeloma. 🧬👉Watch here: https://t.co/5zWftR2zvv #Myeloma #MMSM #ImmunoOnc #HemOnc #LLMCongress2021
-
-
Mashup Score: 1
Ruben Niesvizky, MD, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, discusses future strategies for consolidation therapy in multiple…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ruben Niesvizky (@RubenNiesvizky) of @WeillCornell discusses bispecific antibodies and #CART cell for consolidation therapy in #MultipleMyeloma. ▶️Watch here: https://t.co/COICN6Xa72 #Myeloma #MMSM #ImmunoOnc #HemOnc #LLMCongress2021 #BiTEs
-
Suchita Acharya of @NorthwellHealth comments on current treatments and the role of prophylaxis in rare #BleedingDisorders ➡️Watch here: https://t.co/OMxjXM3Ukm #ImmunoOnc #HemOnc #LLMCongress2021